Spironolactone and colitis: Increased mortality in rodents and in humans
dc.contributor.author | Johnson, Laura A. | en_US |
dc.contributor.author | Govani, Shail M. | en_US |
dc.contributor.author | Joyce, Joel C. | en_US |
dc.contributor.author | Waljee, Akbar K. | en_US |
dc.contributor.author | Gillespie, Brenda W. | en_US |
dc.contributor.author | Higgins, Peter D.R. | en_US |
dc.date.accessioned | 2012-07-12T17:23:35Z | |
dc.date.available | 2013-09-03T15:38:27Z | en_US |
dc.date.issued | 2012-07 | en_US |
dc.identifier.citation | Johnson, Laura A.; Govani, Shail M.; Joyce, Joel C.; Waljee, Akbar K.; Gillespie, Brenda W.; Higgins, Peter D.R. (2012). "Spironolactone and colitis: Increased mortality in rodents and in humans." Inflammatory Bowel Diseases 18(7): 1315-1324. <http://hdl.handle.net/2027.42/92045> | en_US |
dc.identifier.issn | 1078-0998 | en_US |
dc.identifier.issn | 1536-4844 | en_US |
dc.identifier.uri | https://hdl.handle.net/2027.42/92045 | |
dc.description.abstract | Background: Crohn's disease causes intestinal inflammation leading to intestinal fibrosis. Spironolactone is an antifibrotic medication commonly used in heart failure to reduce mortality. We examined whether spironolactone is antifibrotic in the context of intestinal inflammation. Methods: In vitro, spironolactone repressed fibrogenesis in transforming growth factor beta (TGF‐β)‐stimulated human colonic myofibroblasts. However, spironolactone therapy significantly increased mortality in two rodent models of inflammation‐induced intestinal fibrosis, suggesting spironolactone could be harmful during intestinal inflammation. Since inflammatory bowel disease (IBD) patients rarely receive spironolactone therapy, we examined whether spironolactone use was associated with mortality in a common cause of inflammatory colitis, Clostridium difficile infection (CDI). Results: Spironolactone use during CDI infection was associated with increased mortality in a retrospective cohort of 4008 inpatients (15.9% vs. 9.1%, n = 390 deaths, P < 0.0001). In patients without liver disease, the adjusted odds ratio (OR) for inpatient mortality associated with 80 mg spironolactone was 1.99 (95% confidence interval [CI]: 1.51–2.63) In contrast to the main effect of spironolactone mortality, multivariate modeling revealed a protective interaction between liver disease and spironolactone dose. The adjusted OR for mortality after CDI was 1.96 (95% CI: 1.50–2.55) for patients without liver disease on spironolactone vs. 1.28 (95% CI: 0.82–2.00) for patients with liver disease on spironolactone when compared to a reference group without liver disease or spironolactone use. Conclusions: We propose that discontinuation of spironolactone in patients without liver disease during CDI could reduce hospital mortality by 2‐fold, potentially reducing mortality from CDI by 35,000 patients annually across Europe and the U.S. (Inflamm Bowel Dis 2011;) | en_US |
dc.publisher | Wiley Subscription Services, Inc., A Wiley Company | en_US |
dc.subject.other | Crohn's Disease | en_US |
dc.subject.other | Clostridium Difficile | en_US |
dc.subject.other | Colitis | en_US |
dc.subject.other | Mortality | en_US |
dc.subject.other | Spironolactone | en_US |
dc.title | Spironolactone and colitis: Increased mortality in rodents and in humans | en_US |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | en_US |
dc.subject.hlbsecondlevel | Internal Medicine and Specialties | en_US |
dc.subject.hlbtoplevel | Health Sciences | en_US |
dc.description.peerreviewed | Peer Reviewed | en_US |
dc.contributor.affiliationum | Assistant Professor in Gastroenterology, Division of Gastroenterology and Hepatology, Department of Internal Medicine, University of Michigan Medical Center, SPC 5682, Room 6510D, Medical Science Research Building One, 1150 West Medical Center Dr., Ann Arbor, MI 48109‐0682 | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Biostatistics, School of Public Health, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationum | University of Michigan, Department of Internal Medicine, Ann Arbor, Michigan | en_US |
dc.contributor.affiliationother | Medical College of Wisconsin, Department of Dermatology, Milwaukee, Wisconsin | en_US |
dc.identifier.pmid | 22081497 | en_US |
dc.description.bitstreamurl | http://deepblue.lib.umich.edu/bitstream/2027.42/92045/1/21929_ftp.pdf | |
dc.identifier.doi | 10.1002/ibd.21929 | en_US |
dc.identifier.source | Inflammatory Bowel Diseases | en_US |
dc.identifier.citedreference | Sungaila I, Bartle WR, Walker SE, et al. Spironolactone pharmacokinetics and pharmacodynamics in patients with cirrhotic ascites. Gastroenterology. 1992; 102: 1680 – 1685. | en_US |
dc.identifier.citedreference | Andres PG, Friedman LS. Epidemiology and the natural course of inflammatory bowel disease. Gastroenterol Clin North Am. 1999; 28: 255 – 281, vii. | en_US |
dc.identifier.citedreference | Sands BE, Arsenault JE, Rosen MJ, et al. Risk of early surgery for Crohn's disease: implications for early treatment strategies. Am J Gastroenterol. 2003; 98: 2712 – 2718. | en_US |
dc.identifier.citedreference | Louis E, Collard A, Oger AF, et al. Behaviour of Crohn's disease according to the Vienna classification: changing pattern over the course of the disease. Gut. 2001; 49: 777 – 782. | en_US |
dc.identifier.citedreference | Powell DW, Mifflin RC, Valentich JD, et al. Myofibroblasts. II. Intestinal subepithelial myofibroblasts. Am J Physiol. 1999; 277: C183 – 201. | en_US |
dc.identifier.citedreference | Thannickal VJ, Lee DY, White ES, et al. Myofibroblast differentiation by transforming growth factor‐beta1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase. J Biol Chem. 2003; 278: 12384 – 12389. | en_US |
dc.identifier.citedreference | Huang EH, Johnson LA, Eaton K, et al. Atorvastatin induces apoptosis in vitro and slows growth of tumor xenografts but not polyp formation in MIN mice. Dig Dis Sci. 2010; 55: 3086 – 3094. | en_US |
dc.identifier.citedreference | Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real‐time quantitative PCR and the 2(‐Delta Delta C(T)) method. Methods. 2001; 25: 402 – 408. | en_US |
dc.identifier.citedreference | Kim K, Johnson LA, Jia C, et al. Noninvasive ultrasound elasticity imaging (UEI) of Crohn's disease: animal model. Ultrasound Med Biol. 2008; 34: 902 – 912. | en_US |
dc.identifier.citedreference | Higgins PD, Johnson LA, Luther J, et al. Prior Helicobacter pylori infection ameliorates Salmonella typhimurium‐induced colitis: mucosal crosstalk between stomach and distal intestine. Inflamm Bowel Dis. 2011; 17: 1398 – 1408. | en_US |
dc.identifier.citedreference | Kamath PS, Wiesner RH, Malinchoc M, et al. A model to predict survival in patients with end‐stage liver disease. Hepatology. 2001; 33: 464 – 470. | en_US |
dc.identifier.citedreference | Semler DE, Chengelis CP, Radzialowski FM. The effects of chronic ingestion of spironolactone on serum thyrotropin and thyroid hormones in the male rat. Toxicol Appl Pharmacol. 1989; 98: 263 – 268. | en_US |
dc.identifier.citedreference | Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40: 373 – 383. | en_US |
dc.identifier.citedreference | Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD‐9‐CM administrative databases. J Clin Epidemiol. 1992; 45: 613 – 619. | en_US |
dc.identifier.citedreference | Ochs HR, Greenblatt DJ, Bodem G, et al. Spironolactone. Am Heart J. 1978; 96: 389 – 400. | en_US |
dc.identifier.citedreference | Overdiek HW, Hermens WA, Merkus FW. New insights into the pharmacokinetics of spironolactone. Clin Pharmacol Ther. 1985; 38: 469 – 474. | en_US |
dc.identifier.citedreference | Patel SM, Stashefsky E, Maroun MC, et al. The impact of angiotensin‐converting enzyme inhibitors and angiotensin‐receptor blockers in patients with Clostridium difficile infection. Med Hypotheses. 2011; 76: 813 – 815. | en_US |
dc.identifier.citedreference | Carter GP, Rood JI, Lyras D. The role of toxin A and toxin B in Clostridium difficile‐associated disease: past and present perspectives. Gut Microbes. 2010; 1: 58 – 64. | en_US |
dc.identifier.citedreference | Lyras D, O'Connor JR, Howarth PM, et al. Toxin B is essential for virulence of Clostridium difficile. Nature. 2009; 458: 1176 – 1179. | en_US |
dc.identifier.citedreference | Lyerly DM, Saum KE, MacDonald DK, et al. Effects of Clostridium difficile toxins given intragastrically to animals. Infect Immun. 1985; 47: 349 – 352. | en_US |
dc.identifier.citedreference | Kuehne SA, Cartman ST, Heap JT, et al. The role of toxin A and toxin B in Clostridium difficile infection. Nature. 2010; 467: 711 – 713. | en_US |
dc.identifier.citedreference | Witteck A, Yao Y, Fechir M, et al. Rho protein‐mediated changes in the structure of the actin cytoskeleton regulate human inducible NO synthase gene expression. Exp Cell Res. 2003; 287: 106 – 115. | en_US |
dc.identifier.citedreference | Chun TY, Bloem LJ, Pratt JH. Aldosterone inhibits inducible nitric oxide synthase in neonatal rat cardiomyocytes. Endocrinology. 2003; 144: 1712 – 1717. | en_US |
dc.identifier.citedreference | Ibrahim MA, Ashour OM, Ibrahim YF, et al. Angiotensin‐converting enzyme inhibition and angiotensin AT(1)‐receptor antagonism equally improve doxorubicin‐induced cardiotoxicity and nephrotoxicity. Pharmacol Res. 2009; 60: 373 – 381. | en_US |
dc.identifier.citedreference | Fan Q, Liao J, Kobayashi M, et al. Candesartan reduced advanced glycation end‐products accumulation and diminished nitro‐oxidative stress in type 2 diabetic KK/Ta mice. Nephrol Dial Transplant. 2004; 19: 3012 – 3020. | en_US |
dc.identifier.citedreference | Tian B, Liu J, Bitterman P, et al. Angiotensin II modulates nitric oxide‐induced cardiac fibroblast apoptosis by activation of AKT/PKB. Am J Physiol Heart Circ Physiol. 2003; 285: H1105 – 1112. | en_US |
dc.identifier.citedreference | Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to Clostridium difficile. Clin Infect Dis. 2002; 34: 346 – 353. | en_US |
dc.identifier.citedreference | Jarvis WR, Schlosser J, Jarvis AA, et al. National point prevalence of Clostridium difficile in US health care facility inpatients, 2008. Am J Infect Control. 2009; 37: 263 – 270. | en_US |
dc.identifier.citedreference | Pitt B, Zannad F, Remme WJ, et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999; 341: 709 – 717. | en_US |
dc.identifier.citedreference | Tox U, Steffen HM. Impact of inhibitors of the Renin‐Angiotensin‐aldosterone system on liver fibrosis and portal hypertension. Curr Med Chem. 2006; 13: 3649 – 3661. | en_US |
dc.identifier.citedreference | Mezzano SA, Ruiz‐Ortega M, Egido J. Angiotensin II and renal fibrosis. Hypertension. 2001; 38: 635 – 638. | en_US |
dc.identifier.citedreference | Rajagopalan S, Pitt B. Aldosterone as a target in congestive heart failure. Med Clin North Am. 2003; 87: 441 – 457. | en_US |
dc.identifier.citedreference | Gullulu M, Akdag I, Kahvecioglu S, et al. Aldosterone blockage in proliferative glomerulonephritis prevents not only fibrosis, but proliferation as well. Ren Fail. 2006; 28: 509 – 514. | en_US |
dc.identifier.citedreference | Ersoy R, Celik A, Yilmaz O, et al. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats. Perit Dial Int. 2007; 27: 424 – 431. | en_US |
dc.identifier.citedreference | Nishimura H, Ito Y, Mizuno M, et al. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model. Am J Physiol Renal Physiol. 2008; 294: F1084 – 1093. | en_US |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.